SEHK:2269Life Sciences
Assessing WuXi Biologics (SEHK:2269) Valuation As Undervaluation Narrative Gains Traction
What WuXi Biologics (Cayman) SEHK:2269 offers investors right now
WuXi Biologics (Cayman) SEHK:2269 gives you exposure to a global contract research, development, and manufacturing business in biologics, backed by HK$21,790.018 million in revenue and HK$4,908.343 million in net income.
See our latest analysis for WuXi Biologics (Cayman).
At a share price of HK$33.7, WuXi Biologics (Cayman) has a 30 day share price return of 4.14%, while the 1 year total shareholder return of 45.89% contrasts...